Rhythm製藥 RYTM 深 滬
等待開盤 03-26 09:30:00 美东时间
84.62
+2.030
+2.46%
華盛通- 最 高84.85
- 今 開82.60
- 成交量 115.44万股
- 最 低 80.99
- 昨 收 82.59
- 總市值 57.78亿
- 52周最高 122.20
- 市盈率 靜 --
- 換手率 1.69%
- 52周最低 45.905
- 委 比 -32.29%
- 總股本 6828.50万
- 歷史最高 122.20
- 量 比 0.82
- 振 幅 4.67%
- 歷史最低 3.04
- 每 手 1
- 風險率 19.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy
FDA expands Rhythm Pharmaceuticals Imcivree approval for rare hypothalamic obesity, showing strong weight loss results.
03-20 21:40
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $152 to $155.
03-20 20:37
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Why Playboy Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Playboy (PLBY) shares rise in pre-market trading after reporting better-than-expected Q4 results. Other gainers include PTOR, LNAI, LIDR, ISPC, WNW, JVA, NUAI, XLO, and BW. Losers include PRSO, DFLI, LNSR, and MVST.
03-18 00:19
Rhythm Pharmaceuticals Rare Obesity Drug Study Disappoints
Rhythm Pharmaceuticals says EMANATE trial misses goals, despite BMI reduction signals and continued pipeline development plans.
03-17 19:12
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $143
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $136 to $143.
03-12 21:03
